MitraClip: Why, How, and For Whom?

Similar documents
Secondary Mitral Regurgitation: When Should We Intervene?

Valvular Guidelines: The Past, the Present, the Future

Mitral Regurgitation

Mitral Valve Disease, When to Intervene

Understanding the guidelines for Interventions in MR. Ali AlMasood

Percutaneous Mitral Valve Repair: What Can We Treat and What Should We Treat

Minimally invasive therapies for the mitral valve: How will you incorporate into your clinical practice? Guilherme F.

Prognostic Impact of FMR

Percutaneous Mitral Valve Repair

PERCUTANEOUS MITRAL VALVE THERAPIES 13 TH ANNUAL CARDIAC, VASCULAR AND STROKE CARE CONFERENCE PIEDMONT ATHENS REGIONAL

Outcomes of the Initial Experience with Commercial Transcatheter Mitral Valve Repair in the U.S.

Status Of The MitraClip: Trials (EVEREST II & COAPT) & FDA

CARDIOLOGY GRAND ROUNDS

Reshape/Coapt: do we need more? Prof. J Zamorano Head of Cardiology University Hospital Ramon y Cajal, Madrid

Valvular Intervention

Percutaneous Repair for MR:

Severe Asymptomatic Aortic Stenosis

Repair or Replacement

Transcatheter Mitral Valve Repair: today and tomorrow Sponsored by Abbott. Chairperson: M. Haude Panellists: A. Al Nooryani, M.

What is the Role of Surgical Repair in 2012

Valve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries.

TREATMENT OF MITRAL REGURGITATION RAJA NAZIR FACC

Catheter-based mitral valve repair MitraClip System

Outline 9/17/2016. Advances in Percutaneous Mitral Valve Repair and Replacement. Scope of the Problem and Guidelines

GDMT for percutaneous mitral valve repair

Transcatheter Mitral Valve Repair and Replacement: Where is the Latest Randomized Evidence Taking US Mitral-Fr, COAPT

Asymptomatic Valvular Disease:

Mitral Valve Reference Center. Ariana González Gómez Heart Valve Clinic. University Hospital Ramón y Cajal. Madrid. Spain.

When is it too late to perform transcatheter mitral valve repair? Alec Vahanian, FESC,FRCP(Edin.) Bichat hospital University Paris VII

How does Pulmonary Hypertension Affect the Decision to Intervene in Mitral Valve Disease? NO DISCLOSURE

Treatment options in ischaemic mitral regurgitation: surgery, clips, devices?

Valve Disease. Valve Surgery. In 2015, Cleveland Clinic surgeons performed 2943 valve surgeries.

Steven F Bolling Professor of Cardiac Surgery University of Michigan

Transcatheter Valve Replacement: Current State in 2017

PERCUTANEOUS MITRAL VALVE REPAIR IN HIGH RISK PATIENTS - THE SWISS EXPERIENCE AFTER THE FIRST 100 PATIENTS

TAVR: Intermediate Risk Patients

Mitral valve treatment in advanced heart failure: Repair, Replacement, MitraClip. Nicola Buzzatti, MD San Raffaele Scientific Institute Milan, Italy

Valvular Heart Disease Transcatheter Valve Therapies. October 2016 Brian Whisenant MD

Τελικά επιδιόρθωση, αντικατάσταση ή clip στην ισχαιμική ανεπάρκεια Μιτροειδούς; ΒΛΑΣΗΣ ΝΙΝΙΟΣ MD MRCP ΚΛΙΝΙΚΗ ΑΓΙΟΣ ΛΟΥΚΑΣ

Functional Mitral Regurgitation; therapeutic continuum overview. Michele Senni. Cardiologia 1 Scompenso e Trapianti di Cuore A.O. PAPA GIOVANNI XXIII

CLIP ΜΙΤΡΟΕΙ ΟΥΣ: ΠΟΥ ΒΡΙΣΚΟΜΑΣΤΕ;

Chapter 24: Diagnostic workup and evaluation: eligibility, risk assessment, FDA guidelines Ashwin Nathan, MD, Saif Anwaruddin, MD, FACC Penn Medicine

TAVI and TAVR: Radical and Revolutionary: The Newest Insights for the CV Community and a Panel Discussion

Update on Percutaneous Therapies for Structural Heart Disease. William Thomas MD Director of Structural Heart Program Tucson Medical Center

Disclosure Statement of Financial Interest Saibal Kar, MD, FACC

The Mitral Revolution: Transcatheter Repair (and Replacement?) Going Mainstream

2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease

Mitral regurgitation (MR) is the most common

Professor and Chief, Division of Cardiac Surgery Chief Medical Officer, Harpoon Medical. The Houston Aortic Symposium February 23-25, 2017

Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal

Current status: Percutaneous mitral valve therapy

ΔΙΑΔΕΡΜΙΚΗ ΑΝΤΙΜΕΤΩΠΙΣΗ ΔΟΜΙΚΩΝ ΠΑΘΗΣΕΩΝ: Ο ΡΟΛΟΣ ΤΗΣ ΑΠΕΙΚΟΝΙΣΗΣ ΣΤΟ ΑΙΜΟΔΥΝΑΜΙΚΟ ΕΡΓΑΣΤΗΡΙΟ ΣΤΗΝ ΤΟΠΟΘΕΤΗΣΗ MITRACLIP

Severe Left Ventricular Dysfunction: Evolving Revascularization Strategies

Percutaneous Tricuspid Valve Therapies: The Next Frontier? Is the Tricuspid Valve Relevant? Data and Guidelines for TV Interventions

Tissue vs Mechanical What s the Data??

Secondary MR joint with the mitral academy. What is new in our understanding of this disease? Luc Pierard University Hospital, Liège

Severe left ventricular dysfunction and valvular heart disease: should we operate?

Primary Mitral Regurgitation

Percutaneous Management of Severe AS in Octagenarians. Phillip Matsis FRACP FCSANZ Interventional Cardiologist Wakefield Heart Centre Wellington

Contemporary Management of Mitral Regurgitation Tailoring Treatment to The Patient Subset & Clinical Situation

Alec Vahanian,FESC, FRCP (Edin.) Bichat Hospital University Paris VII, Paris, France

Options for my no option Patients Treating Heart Conditions Via a Tiny Catheter

Organic mitral regurgitation

Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute

Percutaneous Therapy for Mitral Regurgitation: Current and Future Options: Could we do better today?

Ischemic Mitral Valve Disease: Repair, Replace or Ignore?

Surgical Ablation: Which Lesion Set for Which Patient?

Burden of Mitral Regurgitation (MR) in the US Why is This Important?

CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?

Is it Time for a National Network of Valve Centers? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH

Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients

Surgical Mininvasive Approach for Mitral Repair Prof. Mauro Rinaldi

Measuring the risk in valve patients Lessons learnt from the TAVI story? Bernard Iung Bichat Hospital, Paris, France

Surgical Indications of Infective Endocarditis in Children

William A. Gray MD System Chief of Cardiovascular Services, Main Line Health President, Lankenau Heart Institute Wynnewood, Pennsylvania USA

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Next Generation Therapies: Aortic, Mitral and Beyond

Indication, Timing, Assessment and Update on TAVI

2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR

Latest therapies for patients with HF. Dr AIGUL BALTABAEVA PhD, FESC, FRCP RBHT & ASPH

Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School

Percutaneous Mitral Valve Repair

TAVR IN INTERMEDIATE-RISK PATIENTS

Mitral regurgitation (MR) is the second most

I have financial relationships to disclose Honoraria from: Edwards

(Ann Thorac Surg 2008;85:845 53)

Eulogio Garcia MD Hospital Clínico San Carlos Madrid - Spain

Emerging Mitral Technologies Where Are We Now? MICHAEL MACK, MD BAYLOR SCOTT & WHITE HEALTH DALLAS, TX

Transcatheter Mitral Valve for fmr: The Era of Too Many Options

Late secondary TR after left sided heart disease correction: is it predictibale and preventable

1. Technology Name: WATCHMAN Left Atrial Appendage Closure Technology. 3. Trade Brand of Technology: WATCHMAN Left Atrial Appendage Closure Technology

Preparing for Your Transcatheter Mitral Valve Repair Procedure

Neal Kleiman, MD Houston Methodist DeBakey Heart and Vascular Institute

Rebuttal. Jerónimo Farré MD 2010

Clinical Practice Guidelines and the Under Treatment of Concomitant AF Vinay Badhwar, MD

Transcatheter Aortic Valve Replacement

Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας

Treatment for functional mitral regurgitation

TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central

Surgical Approach To Functional MR: One Size Does Not Fit All

Transcription:

MitraClip: Why, How, and For Whom? Robert O. Bonow, MD, MS Northwestern University Feinberg School of Medicine Bluhm Cardiovascular Institute Northwestern Memorial Hospital Editor-in-Chief, JAMA Cardiology No Relationships to Disclose

3DTEE in Intraoperative Echo

MitraClip Device (Clip) MitraClip System Clip Delivery System Arm Steerable Guide Handle Gripper Delivery Catheter Handle Steerable Guide, Steerable Sleeve, and Delivery Catheter Stabilizer MitraClip Device (Clip)

Boekstegers et al. Clin Res Cardiol 2013

6mm

LA view LV view

Maisano et al, J Am Coll Cardiol 2013;90:1904-1912

Maisano et al, J Am Coll Cardiol 2013;62:1052-1061

Mitral regurgitation Degenerative MR: primary valve disease Functional MR: primary myocardial disease

Mitral regurgitation Primary mitral regurgitation Secondary mitral regurgitation

Mitral regurgitation Primary mitral regurgitation Secondary mitral regurgitation

Secondary mitral regurgitation Guideline-directed medical therapy for heart failure, including CRT Indications for mitral valve surgery: Patients with severe MR undergoing CABG or AVR Severe MR, persistent symptoms despite optimal medical therapy, including CRT Patients with moderate MR undergoing CABG or AVR class I class IIa class IIb class IIb

Mitral regurgitation Indications for transcatheter MV repair for severe secondary MR: Severe secondary MR Severely symptomatic Prohibited or high surgical risk Reasonable life expectancy class IIb

Prevalence of MR in Patients with LV Dysfunction N Prevalence MR Yiu et al Circulation 2000 128 63% Grigioni et al Circulation 2001 303 64% Koelling et al Am Heart J 2002 1436 49% Trichon et al Am J Cardiol 2003 2057 56% Robbins et al Am J Cardiol 2003 221 59% Cleland et al N Engl J Med 2004 605 50% Grayburn et al J Am Coll Cardiol 2005 336 77% Bursi et al Circulation 2005 303 50% Acker et al J Thorac CV Surg 2006 300 66% Di Mauro et al Ann Thorac Surg 2006 239 75% Rossi et al Heart 2011 1300 74% Deja et al Circulation 2012 599 63% Onishi et al Circ Heart Fail 2013 277 48% * Patients with moderate to severe MR * * *

Survival (percent) Secondary mitral regurgitation can be repaired. But should it be repaired? 100 80 60 40 Medical Surgical n=419 20 0 p=ns 0 500 1000 1500 2000 1 2 3 4 5 6 7 8 Time (days) Wu et al. J Am Coll Cardiol 2005;45:381-387

Mitral regurgitation Primary mitral regurgitation Secondary mitral regurgitation

Mitral regurgitation Indications for transcatheter MV repair for severe primary MR: Chronic severe MR Severely symptomatic Prohibited surgical risk Reasonable life expectancy class IIb

Grade 2 n=564 Grade 4 Grade 1 Grade 3 Mitral Regurgitation Sorajja et al. STS/ACC TVT Registry

Mitral regurgitation Indications for MV surgery for severe primary MR: Repair better than mitral valve replacement class I Repair is preferred treatment when durable class I

Mitral regurgitation Indications for MV surgery for severe primary MR: Repair better than mitral valve replacement class I! Patients should be referred to centers experienced in repair class I Repair is preferred treatment when durable class I

INTERVENTIONAL CARDIOLOGY AND SURGERY Mitral repair best practice: proposed standards B Bridgewater, T Hooper, C Munsch, S Hunter, U von Oppell, S Livesty, B Keogh, F Wells, M Patrick, J Kneeshaw, J Chambers, N Masani, S Ray Heart 2006;92:939-944 Rigorous criteria 19 criteria for best practice: Surgical training Intraoperative echocardiography Volume thresholds Audit Cardiology and imaging Surgeon: >25/yr Hospital: >50/yr Operative mortality <1% 5 year reoperation <5%

Percent Repaired ADULT CARDIAC 100 Mitral Regurgitation 2005-2007 28,507 patients 1,088 surgeons 639 hospitals 80 60 Mean rate of repair: 41% Median number of MV operations: 5 40 20 0 >50/year: 16 surgeons >100/year: 3 surgeons 0 50 100 Mitral Valve Operations per Year 150

Percent Repaired ADULT CARDIAC 28,507 patients 1,088 surgeons 639 hospitals 100 90 80 70 60 50 Are volume thresholds or variations in 40 care associated with short-term and 30 long-term patient outcomes? 20 20 10 0 1 Mitral Regurgitation 2005-2007 5 10 15 20 30 40 50 60 70 80 90100 Mitral Valve Operations per Year 87 88 89 90 Bolling et al, Ann Thorac Surg 2010;90:1904-1912

Median Annual Hospital Volume 150 125 125 100 100 75 75 50 50 25 25 0 Hospital

Median Annual Hospital Volume Median Annual Surgeon Volume 150 60 60 125 125 100 100 75 75 50 50 25 25 50 50 40 40 30 30 20 20 10 10 0 Hospital 0 0 Surgeon

Mitral Repair Rate (%) 100 100 90 80 80 70 60 60 50 40 40 30 20 20 10 0 0 Surgeon

Medicare data 2000-2009 1239 hospitals performing MV surgery Number of MV operations/year: 91% performed 40 51% performed 10 29% performed 5 Number of MV repairs/year: 94% performed 20 65% performed 5 23% performed 1

Mitral Regurgitation Percutaneous Edge-to-Edge Repair Incomplete percutaneous repair with residual MR probably inferior to complete successful surgical repair Incomplete percutaneous repair probably equivalent to incomplete surgical repair with residual MR Incomplete percutaneous repair probably superior to mitral valve replacement

Centers of Excellence in Mitral Valve Repair Criteria: MV surgery volume requirement (center and surgeon) Expert periprocedural imaging capabilities Access to transcatheter technology Transparency regarding outcomes including: repair rates, mortality rates, stroke rates, repair durability